Buy Cadilap 250mg - Lapatinib Tablets Online, Cadilap 250mg

Wishlist(0)

Cadilap 250mg - Lapatinib Tablets

Cadilap 250mg contains Lapatinib, a targeted therapy used to treat HER2-positive breast cancer. It works by blocking cancer cell growth signals, particularly in patients who have not responded to other treatments.

Select your size:

250mg

Choose Quantity:

+ Add To Cart

Buy Now

Add to wishlist

Description Product Details

General Information:

Generic Name: Lapatinib

Brand Name: Cadilap 250mg

Packing: Bottle of 30 or 60 tablets (depending on manufacturer)

Strength: 250mg

Manufacturer: Cadila Healthcare Ltd.

Form: Oral Tablet

Category: Anti-cancer, Tyrosine Kinase Inhibitor

Product Intro:

Cadilap 250mg is an oral cancer medication containing Lapatinib, a dual tyrosine kinase inhibitor. It is primarily used for the treatment of advanced or metastatic breast cancer in patients with overexpression of HER2. Often used in combination with other therapies, it slows down or stops the growth of cancerous cells.

Uses:

Cadilap 250mg is used in the treatment of:

HER2-positive metastatic breast cancer
Advanced-stage breast cancer after progression on prior therapy
Breast cancer in combination with capecitabine
Breast cancer in combination with letrozole for hormone receptor-positive tumors
Investigational use in HER2-positive gastric cancer
Other HER2-overexpressing solid tumors under clinical trials

Storage Instructions:

Store below 30°C in a dry place
Protect from light and moisture
Keep out of reach of children
Do not use after expiry date

How it Works (Mechanism of Action):

Lapatinib inhibits the intracellular kinase domains of both EGFR (ErbB1) and HER2 (ErbB2) receptors. This dual inhibition blocks signal transduction pathways involved in cell proliferation and survival, which are often overactive in HER2-positive breast cancer cells.

Side Effects:

Common Side Effects:

Diarrhea
Nausea
Rash
Fatigue
Loss of appetite
Hand-foot syndrome

Severe Side Effects:

Liver toxicity (elevated liver enzymes)
Cardiotoxicity (decreased left ventricular ejection fraction)
Severe skin reactions
Interstitial lung disease
QT prolongation (irregular heart rhythm)

Dosage (Typical Recommended Dose):

Standard dose: 1,250 mg (five tablets of 250mg) once daily
Should be taken continuously unless advised otherwise
Dose may vary when combined with other medications (e.g., Capecitabine or Letrozole)

Method of Administration:

Take orally on an empty stomach, either 1 hour before or 1 hour after a meal
Swallow tablets whole with water
Take the dose at the same time each day

Precautions:

Monitor liver function before and during treatment
Cardiac monitoring in patients with heart history
Avoid alcohol and grapefruit products
Use reliable contraception during and for at least 1 week after treatment
Not recommended during pregnancy or breastfeeding

Drug Interactions:

CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase drug levels
CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease effectiveness
Antacids or PPIs may interfere with absorption
Caution with drugs that prolong QT interval (e.g., amiodarone, haloperidol)

Allergies:

Avoid use in patients with known hypersensitivity to Lapatinib
Monitor for allergic reactions like skin rash, itching, facial swelling, or difficulty breathing

Overdose Information:

Overdose symptoms may include severe diarrhea, vomiting, liver dysfunction
Seek immediate medical help or contact a poison control center

Missed Dose Instructions:

Take the missed dose as soon as you remember, unless it's close to your next dose
Do not double the dose to make up for a missed one

Additional Notes:

Regular blood tests are needed to monitor liver and heart function
Notify your doctor of any new symptoms during treatment
Adherence to dosage schedule is crucial for optimal efficacy